Clinical Trial Update: Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase [Phase 3]

View source ↗

Summary

A Phase 3 trial assessing fingolimod for relapsing-remitting multiple sclerosis, reporting efficacy and safety with an optional extension phase.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Fingolimod (fingolimod)

Snippet

Sponsor: Novartis | Conditions: Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2011-05-16